Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496340 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Pentostatin and Targeted Busulfan
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00496340 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 42 participants.
The verdict
NCT00496340, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The objective of this trial is to determine whether a regimen of pentostatin and busulfan (IV) can facilitate engraftment of human leukocyte antigen (HLA) partially compatible siblings and unrelated donor transplants by using CD4+ laboratory-guided immunosuppression among 41 transplant patients meeting the inclusion criteria.
Interventions
- DRUG Busulfan
- DRUG Rituximab
- DRUG Pentostatin
- PROCEDURE Allogeneic Hematopoietic Cell Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2007-07 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00496340
The ClinicalTrials.gov registry entry for NCT00496340 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Busulfan is the first listed.
NCT00496340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00496340 about?
NCT00496340 is a clinical study titled "Phase II Trial of Pentostatin and Targeted Busulfan". The objective of this trial is to determine whether a regimen of pentostatin and busulfan (IV) can facilitate engraftment of human leukocyte antigen (HLA) partially compatible siblings and unrelated donor transplants by using CD4+ laboratory-guided immunosuppression among 41 transplant patients meet...
What is the current status of trial NCT00496340?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2007-07. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00496340?
The interventions under investigation include: Busulfan (DRUG), Rituximab (DRUG), Pentostatin (DRUG), Allogeneic Hematopoietic Cell Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00496340?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.